Disc Medicine, Inc.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. The company's portfolio targets fundamental biological pathways related to red blood cell formation and function, specifically heme biosynthesis and iron homeostasis. Its lead product candidate, bitopertin, is being developed for erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia. Other pipeline candidates include DISC-0974 for anemia of myelofibrosis and anemia of chronic kidney disease, and DISC-3405 for polycythemia vera and other hematologic disorders. Additionally, Disc Medicine has a preclinical program, DISC-0998, targeting anemia associated with inflammatory diseases.

Disc Medicine, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol IRON. The company's financials are reported in United States Dollars (USD), which is the standard currency for companies listed on U.S. exchanges. This listing provides investors with access to trading in a major U.S. stock market, and all transactions are conducted in USD.

Disc Medicine, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and living organisms to develop therapies. In Disc Medicine's case, the company specializes in clinical-stage biopharmaceuticals targeting hematologic (blood-related) diseases. The Biotechnology industry is known for high research and development costs, regulatory hurdles, and the potential for significant breakthroughs in treating serious medical conditions.

Disc Medicine, Inc. is headquartered in Watertown, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its country and region designation. Its operations are focused on developing treatments for serious hematologic diseases, and its clinical trials and commercialization efforts are centered in the United States. The company was founded in 2017 and has since been building a pipeline of product candidates aimed at addressing unmet medical needs in blood disorders.